Industry Leaders

  1. A Different Path To An IPO

    Typically, there are two paths biotechs take when going public — seeking VC funding or raising capital via a reverse merger. However, INmune Bio chose a third path.

  2. Data Analytics Are Unlocking Valuable Cold-Chain Insights

    Much like in many other areas of the drug development continuum, the focus now in the cold chain is on data and how it can be unlocked and analyzed in real time to save money, time, and resources — while also better ensuring patient safety.

  3. Greater Rigor Is Needed To Enable Real-World Evidence To Reach Its Full Potential

    As the industry’s appetite for creating and using data-driven insights to improve clinical outcomes continues to grow, so does the need to integrate and validate disparate data sources. Efforts to impose greater consistency and rigor should be welcomed by all.

  4. AI In Life Sciences — Seeing Past The Hype

    Life science leaders must balance their need to apply AI technologies to improve patient care, and bottom lines — without getting caught-up in the AI hype machine.

  5. Pitching Investors: It’s About You, Not The Slide Deck

    Let’s face it … pitching potential investors is a remarkable opportunity. It could be your one shot at getting your idea or company off the ground, so you better be appealing, tantalizing, and even provocative.

  6. Beyond Capital and Mentoring: Paving The Way For Female Entrepreneurs

    Women who are starting life sciences companies often do not have access to a network of mentors and advisors, whose strong advocacy establishes instant credibility and opens the doors to investors.

  7. Why Soft Skills Are The Key To Better Science And Collaborations

    Here are some examples of why “soft skills,” such as those related to relationship building, leadership, and communication, are essential to today’s pharma and biotech leaders.

  8. As Pediatric Rare Disease Patients Grow Up, Can We Keep Pace?

    Companies frequently talk about being patient-centric. But what I don’t hear discussed as often is the role of the patient after a drug is approved. And I am convinced it is equally important. Why? Because patients are not static; they grow and change over time.

  9. Cell And Gene Therapies: Driving Innovation For Logistical Solutions

    Aside from the clinical opportunity that gene therapy products present; they do introduce tremendous complexity into both the manufacturing and commercial processes. Remember these three points before developing your gene therapy plan.

  10. Is Your Lab Prepared For A Cybersecurity Attack?

    While the costs and reputational implications associated with pharma data breaches are enough to pay heed to cybersecurity, these compromises can pose a serious threat to patient safety.